We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




10-Minute Prostate Specific Antigen Test Provides Early Prostate Cancer Warning

By LabMedica International staff writers
Posted on 20 Jan 2025
Print article
Image: The Fortel Prostate Screening test detects elevated levels of prostate specific antigen using a finger prick blood sample (Photo courtesy of Biomerica)
Image: The Fortel Prostate Screening test detects elevated levels of prostate specific antigen using a finger prick blood sample (Photo courtesy of Biomerica)

Prostate cancer is the second most common cancer among men globally, with 1.4 million new cases diagnosed and 375,000 deaths reported worldwide in 2020. Alarmingly, a new case is diagnosed every two minutes. While significant progress has been made in early detection and research, prostate cancer remains a major public health concern. Elevated levels of prostate-specific antigen (PSA), a substance produced by the prostate and released in trace amounts into the bloodstream, may indicate potential prostate disease. Now, a new test designed to detect elevated PSA levels from a finger-prick blood sample could serve as an early warning sign for prostate cancer.

Biomerica’s (Irvine, CA, USA) Fortel PSA Screening Test is a simple, user-friendly diagnostic tool that provides accurate results within just 10 minutes using a finger-prick blood sample. By measuring elevated PSA levels, a known early indicator of prostate disease, the test helps with the early detection of prostate cancer and other related conditions. This accessible and rapid method aims to improve proactive health management, ease the burden on healthcare systems, and enhance patient outcomes. The Fortel PSA test has shown exceptional performance in rigorous evaluations, with a study reporting 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods. Further studies have validated the test’s effectiveness, showing 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy. These promising results highlight the Fortel PSA test as a reliable and efficient tool for early detection.

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation
New
Microplates
Eppendorf Microplates

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.